The use of radiocobalt as a label improves imaging of EGFR using DOTA-conjugated Affibody molecule.

ABSTRACT: Several anti-cancer therapies target the epidermal growth factor receptor (EGFR). Radionuclide imaging of EGFR expression in tumours may aid in selection of optimal cancer therapy. The ¹¹¹In-labelled DOTA-conjugated Z_EGFR:2377 Affibody molecule was successfully used for imaging of EGFR-expressing xenografts in mice. An optimal combination of radionuclide, chelator and targeting protein may further improve the contrast of radionuclide imaging. The aim of this study was to evaluate the targeting properties of radiocobalt-labelled DOTA-Z_EGFR:2377. DOTA-Z_EGFR:2377 was labelled with ⁵⁷Co (T_1/2 = 271.8 d), ⁵⁵Co (T_1/2 = 17.5 h), and, for comparison, with the positron-emitting radionuclide ⁶⁸Ga (T

SUBMITTER: Garousi J 

PROVIDER: S-EPMC5519605 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature